SEC Filing Summary: Nanobiotix S.A. (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Nanobiotix S.A., a foreign private issuer headquartered in Paris, France, on May 27, 2025. The report covers the month of May 2025 and serves as a notification of transactions by Persons Discharging Managerial Responsibilities (PDMR) and their closely associated persons.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding insider transactions and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely discloses compliance with the EU Market Abuse Regulation (MAR) regarding PDMR transactions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The primary purpose is to attach Exhibit 99.1, which details the specific PDMR notifications.
Key Facts for Investor Verification
- The filing is a compliance report under the EU Market Abuse Regulation (MAR) regarding insider trading disclosures.
- Specific details of the PDMR transactions are located in Exhibit 99.1, which is a translation of the original French filing.
- No financial results or operational updates are included in this specific Form 6-K.
- The report was signed by Bart Van Rhijn, Chief Financial and Business Officer.